New combo therapy aims to fight breast cancer in the bones
NCT ID NCT06374459
Summary
This study is testing whether adding an investigational drug called zunsemetinib to the standard chemotherapy capecitabine is safe and effective for people with a specific type of advanced breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer's growth in the bones and slow down the disease. It is for adults whose cancer has progressed despite prior hormone-based treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.